Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple escalating dose study of BAY 1093884 in adults with hemophilia A or B with or without inhibitors
2017-003324-67Phase 2Terminated
- Sponsor
- Bayer
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of befovacimab in hemophilia A and hemophilia B (HB), sponsored by Bayer. Primary endpoints: Safety (drug-related adverse events), Safety (serious adverse events) and 2 more. Started Mar 2018; status: terminated.
02
Drugs
befovacimab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on 2017-003324-67.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003324-67.